Bladder preservation study for muscle-invasive bladder cancer
Part of Cancer clinical trials.
This study collects information from people with muscle-invasive bladder cancer who have had chemotherapy or immunotherapy and then decided not to have their bladder removed. It looks at different ways to preserve the bladder and how well those approaches work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with muscle-invasive bladder cancer (cancer that has spread into the bladder muscle).
- You have already received chemotherapy or immunotherapy as part of your treatment plan.
- After that treatment, you have chosen not to have surgery to remove your bladder, or you were not able to have it, and you also have not had radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment approach using MRI to guide bladder preservation for patients with muscle-invasive bladder cancer. The goal is to treat the cancer with chemotherapy and radiation instead of removing the bladder, potentially allowing you to keep your bladder while fighting the cancer.
This study looks at different drug treatments given around the time of surgery for muscle-invasive bladder cancer. It aims to understand how well these treatments work and may help guide future care.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial tests a combination of probiotics, targeted therapy (RC48-ADC), and immunotherapy (Toripalimab) to treat muscle-invasive bladder cancer while preserving the bladder. The goal is to see if this combination can shrink or eliminate the cancer without needing bladder removal.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.